UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 27, 2018

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 


 

Illinois

 

1-2189

 

36-0698440

(State or other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 


 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o

 

 

 



 

Item 5.07 — Submission of Matters to a Vote of Security Holders.

 

Abbott held its Annual Meeting of Shareholders on April 27, 2018.  The following is a summary of the matters voted on at that meeting.

 

(1)         The shareholders elected Abbott’s entire Board of Directors.  The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:

 

Name

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

 

 

 

 

 

 

 

 

 

Robert J. Alpern, M.D.

 

1,310,927,186

 

19,098,268

 

226,634,924

 

Roxanne S. Austin

 

1,268,068,024

 

61,957,430

 

226,634,924

 

Sally E. Blount, Ph.D.

 

1,318,171,199

 

11,854,255

 

226,634,924

 

Edward M. Liddy

 

1,295,334,980

 

34,690,474

 

226,634,924

 

Nancy McKinstry

 

1,317,659,954

 

12,365,500

 

226,634,924

 

Phebe N. Novakovic

 

1,305,047,201

 

24,978,253

 

226,634,924

 

William A. Osborn

 

1,288,267,458

 

41,757,996

 

226,634,924

 

Samuel C. Scott III

 

1,288,857,580

 

41,167,873

 

226,634,924

 

Daniel J. Starks

 

1,317,385,198

 

12,640,256

 

226,634,924

 

John G. Stratton

 

1,320,912,106

 

9,113,348

 

226,634,924

 

Glenn F. Tilton

 

1,266,616,454

 

63,409,000

 

226,634,924

 

Miles D. White

 

1,262,425,572

 

67,599,882

 

226,634,924

 

 

(2)         The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors.  The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,540,591,644

 

13,002,291

 

3,066,443

 

0

 

 

(3)         The shareholders voted to approve the compensation of Abbott’s named executive officers listed in the proxy statement for the 2018 annual meeting, with 78.28 percent of the votes cast voting “For” the proposal.  The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,041,167,404

 

279,530,367

 

9,327,683

 

226,634,924

 

 

2



 

(4)         The shareholders rejected a shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director, with 30.76 percent of the votes cast voting “For” the proposal.  The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

409,080,027

 

912,026,962

 

8,918,465

 

226,634,924

 

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBOTT LABORATORIES

 

 

 

 

 

 

Date: April 30, 2018

By:

/s/ Brian B. Yoor

 

 

Brian B. Yoor

 

 

Executive Vice President, Finance

 

 

and Chief Financial Officer

 

4